ImmunoPrecise Antibodies announces new validation study on LENSai

ImmunoPrecise Antibodies (IPA) announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA’s patented HYFT technology. “It’s generally assumed that AI can only make accurate predictions if it has seen similar data before,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody – protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn’t always need massive data to be powerful and accurate – it just needs the right kind.”